Dutch rare diseases biotech firm ProQR Therapeutics (Nasdaq: PRQR) saw its shares leap more than 11% to $2.07 today, after it announced its successful defense against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.
ProQR explained that the opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR’s granted patent EP 3 507 366 B1, which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine.
The Opposition Division of the EPO held a public hearing on April 17, 2024, and ruled such that ProQR’s strong IP position on chemically modified editing oligonucleotides was maintained.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze